The Epidemiology of urological cancer 2001–2013

Roger Kockelbergh, Luke Hounsome*, Erik Mayer

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


Background: The purpose of the NCRAS Urological Cancer Site-Specific Clinical Reference Group (SSCRG) is to link the knowledge of clinicians with the large amount of routine data collected by cancer registration. This study considers the latest available data and trends in incidence, mortality and survival and offers interpretation of findings in a clinical context. Methods: New diagnoses of urological cancer in England for 2001 to 2013 were extracted from the National Cancer Registration and Analysis Service (NCRAS). Deaths were counted from Office for National Statistics (ONS) data for the same years. Directly age-standardised rates (ASRs) and net survival were calculated. Results: Prostate cancer incidence has increased to 40,000 cases per year. Mortality rates are falling and hence the improvement seen in five-year survival is likely to be due to changes in treatment rather than artefact. Bladder cancer (including CIS and pTa disease) shows a stable incidence and decreasing mortality rates. Survival from T1–T4 bladder cancer is stable. There has been a marked rise in kidney cancer incidence in both sexes with a stable mortality. The stable mortality suggests that improved five-year survival may be an artefact due to increased detection as a result of more widespread use of diagnostic imaging. Incidence of upper-urinary-tract cancer has risen both for invasive and non-invasive disease, and mortality in men has risen for invasive disease. This may be down to better recognition and attribution of disease. Testicular cancer has shown little change. Deaths are now rare, and survival is the highest for any cancer. There have been no significant changes in penis cancer, which remains the rarest urological cancer. Conclusion: The epidemiological data suggest a generally improving picture for urological cancer. However, there are some areas which require further consideration. Population-based studies can show variation in rare cancers and highlight previously unrecognised inequalities.

Original languageEnglish
Pages (from-to)3-8
Number of pages6
JournalJournal of Clinical Urology
Issue number1_suppl
Publication statusPublished - 1 Jan 2017


  • bladder cancer
  • kidney cancer
  • penile cancer
  • Prostate cancer
  • testis cancer
  • urological cancer


Dive into the research topics of 'The Epidemiology of urological cancer 2001–2013'. Together they form a unique fingerprint.

Cite this